MX341877B - Compuestos y métodos para tratar influenza. - Google Patents
Compuestos y métodos para tratar influenza.Info
- Publication number
- MX341877B MX341877B MX2012000230A MX2012000230A MX341877B MX 341877 B MX341877 B MX 341877B MX 2012000230 A MX2012000230 A MX 2012000230A MX 2012000230 A MX2012000230 A MX 2012000230A MX 341877 B MX341877 B MX 341877B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- treating influenza
- treating
- directed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
- H01L31/12—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof structurally associated with, e.g. formed in or on a common substrate with, one or more electric light sources, e.g. electroluminescent light sources, and electrically or optically coupled thereto
- H01L31/125—Composite devices with photosensitive elements and electroluminescent elements within one single body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Electromagnetism (AREA)
- Computer Hardware Design (AREA)
- Power Engineering (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Esta invención se dirige a métodos para el tratamiento y prevención de infección por influenza al inhibir los procesos de maduración de virus HA de influenza empleado los compuestos de la fórmula I. También se dirige a combinaciones para el tratamiento y prevención de infección por influenza que comprende compuesto de la fórmula I y otros agentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22089109P | 2009-06-26 | 2009-06-26 | |
PCT/US2010/039638 WO2010151577A1 (en) | 2009-06-26 | 2010-06-23 | Compounds and methods for treating influenza |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012000230A MX2012000230A (es) | 2012-01-25 |
MX341877B true MX341877B (es) | 2016-09-06 |
Family
ID=43381033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000230A MX341877B (es) | 2009-06-26 | 2010-06-23 | Compuestos y métodos para tratar influenza. |
Country Status (16)
Country | Link |
---|---|
US (6) | US9023877B2 (es) |
EP (2) | EP3895706A1 (es) |
JP (3) | JP5932640B2 (es) |
KR (4) | KR20170141830A (es) |
CN (2) | CN108042535A (es) |
AP (1) | AP2012006064A0 (es) |
AU (2) | AU2010264479B2 (es) |
BR (2) | BRPI1014322A2 (es) |
CA (3) | CA2968113C (es) |
EA (1) | EA030679B1 (es) |
ES (1) | ES2914949T3 (es) |
HK (1) | HK1255283A1 (es) |
MX (1) | MX341877B (es) |
PT (1) | PT2445349T (es) |
WO (1) | WO2010151577A1 (es) |
ZA (1) | ZA201200263B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201402281WA (en) | 2009-05-12 | 2014-07-30 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
BRPI1014322A2 (pt) * | 2009-06-26 | 2015-08-25 | Romark Lab Lc | Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. |
JP5837936B2 (ja) * | 2010-11-01 | 2015-12-24 | ロマーク ラボラトリース,エル.シー. | アルキルスルフィニル置換チアゾリド化合物 |
ES2767304T3 (es) * | 2011-05-16 | 2020-06-17 | Romark Laboratories Lc | Utilización de compuestos de tiazolida para la prevención y el tratamiento de enfermedades víricas, cáncer y enfermedades causadas por infecciones intracelulares |
AU2016201747B2 (en) * | 2011-05-16 | 2017-06-01 | Romark Laboratories, L.C. | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
EP3006431B1 (en) * | 2013-07-04 | 2019-01-30 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Tizoxanide carbamate and pharmaceutical use thereof |
CN104771398B (zh) * | 2014-01-09 | 2017-01-18 | 湖南大学 | N‑[5‑(2‑硝基乙基)噻唑‑2‑基]苯甲酰胺及其医药用途 |
JP6633092B2 (ja) | 2014-11-11 | 2020-01-22 | ロマーク ラボラトリーズ,リミティド カンパニー | チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法 |
JP6955648B2 (ja) | 2015-09-01 | 2021-10-27 | ファースト ウェーブ バイオ インコーポレイテッド | 異常炎症反応に関連する状態を処置するための方法および組成物 |
CA3113354A1 (en) * | 2016-03-31 | 2017-10-05 | Romark Laboratories, L.C. | Thiazolide compounds for treating viral infections |
EP3777855B1 (en) | 2016-04-11 | 2022-10-19 | Genfit | Methods of treatment for fibrotic diseases |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US11173149B2 (en) | 2017-04-18 | 2021-11-16 | Romark Laboratories L.C. | Inhibition of protein disulfide-isomerase A3 |
CN107286149B (zh) * | 2017-05-10 | 2021-02-12 | 南华大学 | N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用 |
CN107141267B (zh) * | 2017-06-22 | 2019-04-09 | 湖南大学 | N-(5-酰基噻唑-2-基)酰胺及其制备方法与应用 |
CN107235927B (zh) * | 2017-06-22 | 2019-04-16 | 湖南大学 | N-(5-酰基噻唑-2-基)哌嗪基酰胺及其医药用途 |
KR102077833B1 (ko) * | 2018-12-10 | 2020-02-14 | 류형준 | 기능성 식품조성물 |
US20220193021A1 (en) * | 2019-05-03 | 2022-06-23 | President And Fellows Of Harvard College | Combination therapy for treating influenza virus infection |
JP7320402B2 (ja) | 2019-08-08 | 2023-08-03 | ローム株式会社 | Memsセンサ |
WO2021046446A1 (en) * | 2019-09-06 | 2021-03-11 | Yourchoice Therapeutics, Inc. | Compositions and methods of use for enhancing fertility |
CN112480104B (zh) * | 2019-09-11 | 2024-06-18 | 绍兴君科臻元医药科技有限公司 | 硝唑尼特衍生物及其医药用途 |
JP2023512622A (ja) * | 2020-01-21 | 2023-03-28 | アカデミー オブ ミリタリー メディカル サイエンシズ | ニタゾキサニド及びその活性型であるチゾキサニドのSARS-CoV-2感染症の治療への適用 |
US20230241037A1 (en) * | 2020-03-09 | 2023-08-03 | 1Globe Health Institute, Nanjing | Cross-linked medication for treatment of coronaviral infection and method of treatment |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
RU2726070C1 (ru) * | 2020-03-23 | 2020-07-08 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ патогенетической коррекции метаболических нарушений при инфекционном мононуклеозе, вызванном вирусом Эпштейна-Барр |
US20230143470A1 (en) * | 2020-03-30 | 2023-05-11 | The Scripps Research Institute | Small molecule inhibitors of influenza hemagglutinin |
JP2023537237A (ja) | 2020-07-20 | 2023-08-31 | ロマーク ラボラトリーズ,リミティド カンパニー | チゾキサニドおよび2-ヒドロキシ-n-(5-クロロ-1,3-チアゾル-2-イル)ベンズアミド(rm-4848)とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびn-メチルピペラジンの結晶塩 |
US20230330069A1 (en) | 2020-08-24 | 2023-10-19 | Romark Laboratories, L.C. | Use of thiazolides against coronaviruses |
US20240002332A1 (en) * | 2020-11-18 | 2024-01-04 | Wenwei HUANG | Small Molecule Inhibitors of SARS-CoV-2 Infections |
CN116456980A (zh) * | 2021-03-29 | 2023-07-18 | 北京大学 | 噻唑类化合物在制备治疗和预防癌症药物中的用途 |
WO2022214855A1 (es) * | 2021-04-10 | 2022-10-13 | Siegfried Rhein, S.A. De C.V. | Uso de nitazoxanida para la preparación de medicamento para prevenir o tratar infección causada por coronavirus sars-cov-2 |
CN115197164A (zh) * | 2021-04-12 | 2022-10-18 | 杜心赟 | 新型噻唑类化合物及其制备方法和用途 |
CN113277994A (zh) * | 2021-05-18 | 2021-08-20 | 杜心赟 | 噻唑类化合物及其制备方法和用途 |
CN116898846A (zh) * | 2022-04-12 | 2023-10-20 | 成都贝诺科成生物科技有限公司 | 一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1177206A (en) | 1967-11-28 | 1970-01-07 | Pfizer & Co C | Lung Antiviral Factor |
GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
US4343945A (en) | 1979-01-23 | 1982-08-10 | Olin Corporation | 5-Benzamido-3-trichloromethyl-1,2,4-thiadiazoles and their use as herbicides, fungicides and insecticides |
US4337081A (en) | 1979-01-23 | 1982-06-29 | Olin Corporation | 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides |
SU910628A1 (ru) | 1980-04-22 | 1982-03-07 | Гродненский государственный медицинский институт | Способ получени 2-ациламинотиазолов |
JPS56158703A (en) | 1980-05-10 | 1981-12-07 | Sankyo Co Ltd | Fungicide |
US4416683A (en) | 1980-09-16 | 1983-11-22 | Eli Lilly And Company | Benzamides, compositions and agricultural method |
JPS649978A (en) | 1987-07-02 | 1989-01-13 | Shionogi & Co | Perfluoroalkylisoxazole derivative |
US4874864A (en) | 1988-05-24 | 1989-10-17 | Pfizer Inc. | Benzamide protease inhibitors |
US5169846A (en) | 1989-10-12 | 1992-12-08 | Crooks Michael J | Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators |
AU705226B2 (en) | 1994-01-28 | 1999-05-20 | University Of Kentucky Research Foundation, The | Codrugs as a method of controlled drug delivery |
US5578621A (en) | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
DE69526936T2 (de) * | 1994-04-13 | 2003-02-20 | Romark Lab Lc | Benzamide-derivate, zubereitungen die sie erhalten und ihre anwendung |
US5968961A (en) * | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
DE69809928T2 (de) | 1997-05-07 | 2003-04-24 | Romark Lab Lc | Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen |
GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US6849254B1 (en) * | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
US6136835A (en) * | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
US7229822B1 (en) | 2000-02-29 | 2007-06-12 | Univ Columbia | Melanoma differentation associated gene-5 and vectors and cells containing same |
CA2433018A1 (en) | 2000-12-21 | 2002-06-27 | Joel C. Barrish | Thiazolyl inhibitors of tec family tyrosine kinases |
ATE315555T1 (de) | 2001-05-11 | 2006-02-15 | Pfizer Prod Inc | Thiazolderivate und ihre verwendung als cdk- inhibitoren |
WO2002092584A1 (fr) | 2001-05-14 | 2002-11-21 | Nihon Nohyaku Co., Ltd. | Derives du thiadiazole, pesticides a usage agricole et horticole, et leurs utilisations |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
JP2003335680A (ja) | 2002-05-21 | 2003-11-25 | Otsuka Pharmaceut Factory Inc | Acat−1阻害剤 |
EA008769B1 (ru) | 2002-06-05 | 2007-08-31 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения диабета |
AU2003279010A1 (en) * | 2002-09-28 | 2004-04-19 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US6737382B1 (en) | 2002-10-23 | 2004-05-18 | Nippon Soda Co. Ltd. | Insecticidal aminothiazole derivatives |
US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
JP4432901B2 (ja) | 2003-02-26 | 2010-03-17 | 萬有製薬株式会社 | ヘテロアリールカルバモイルベンゼン誘導体 |
EP1611128A2 (en) | 2003-03-28 | 2006-01-04 | Pharmacia & Upjohn Company LLC | Positive allosteric modulators of the nicotinic acetylcholine receptor |
US20070042997A1 (en) | 2003-07-16 | 2007-02-22 | Akiko Itai | Medicament for treatment of dermal pigmentation |
US20050090506A1 (en) | 2003-10-24 | 2005-04-28 | Nippon Soda Co., Ltd. | Insecticidal perfluoroalkylthiazole derivatives |
US7683097B2 (en) | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
UA90864C2 (en) * | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
US20060194853A1 (en) | 2004-10-08 | 2006-08-31 | Rossignol Jean F | Alkyl benzamides |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
CA2604640A1 (en) | 2005-04-12 | 2006-10-19 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
US8088806B2 (en) | 2005-05-09 | 2012-01-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
ES2525217T3 (es) | 2005-06-27 | 2014-12-19 | Exelixis Patent Company Llc | Moduladores de LXR basados en imidazol |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
MX2008001605A (es) | 2005-08-02 | 2008-04-14 | Irm Llc | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. |
AU2006330924B2 (en) | 2005-12-21 | 2012-03-15 | Abbvie Inc. | Anti-viral compounds |
ZA200806310B (en) | 2006-01-09 | 2009-12-30 | Romark Lab Lc | Viral hepatitis treatment |
CA2649577A1 (en) | 2006-04-28 | 2007-11-08 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
MX2008015217A (es) | 2006-05-31 | 2008-12-12 | Abbott Lab | Compuestos de tiazol como ligandos del receptor de canabinoides y usos de los mismos. |
EP2041116A1 (de) | 2006-07-07 | 2009-04-01 | Boehringer Ingelheim International GmbH | Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel |
US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
WO2008070707A1 (en) | 2006-12-05 | 2008-06-12 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
PT2178852E (pt) * | 2007-08-03 | 2015-11-12 | Romark Lab Lc | Compostos tiazolida substituídos com alquilsulfonilo |
WO2009065096A1 (en) | 2007-11-16 | 2009-05-22 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
US20100081713A1 (en) * | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JP2011524365A (ja) | 2008-06-11 | 2011-09-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | マラリアの処置に有用な化合物および組成物 |
TW201014860A (en) | 2008-09-08 | 2010-04-16 | Boehringer Ingelheim Int | New chemical compounds |
UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
CN102282138A (zh) | 2008-11-19 | 2011-12-14 | 先灵公司 | 二酰基甘油酰基转移酶的抑制剂 |
ES2528946T3 (es) * | 2009-03-20 | 2015-02-13 | University Of Virginia Patent Foundation | Benzotiofeno-nitrotiazolida y otros antimicrobianos de amplio espectro |
SG10201402281WA (en) | 2009-05-12 | 2014-07-30 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
BRPI1014322A2 (pt) * | 2009-06-26 | 2015-08-25 | Romark Lab Lc | Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. |
-
2010
- 2010-06-23 BR BRPI1014322-0A patent/BRPI1014322A2/pt not_active Application Discontinuation
- 2010-06-23 KR KR1020177036332A patent/KR20170141830A/ko active Application Filing
- 2010-06-23 CA CA2968113A patent/CA2968113C/en active Active
- 2010-06-23 EA EA201270077A patent/EA030679B1/ru unknown
- 2010-06-23 AU AU2010264479A patent/AU2010264479B2/en active Active
- 2010-06-23 ES ES10792599T patent/ES2914949T3/es active Active
- 2010-06-23 BR BR122020003634A patent/BR122020003634B8/pt active IP Right Grant
- 2010-06-23 EP EP21174646.6A patent/EP3895706A1/en not_active Withdrawn
- 2010-06-23 MX MX2012000230A patent/MX341877B/es active IP Right Grant
- 2010-06-23 WO PCT/US2010/039638 patent/WO2010151577A1/en active Application Filing
- 2010-06-23 CN CN201611234246.0A patent/CN108042535A/zh active Pending
- 2010-06-23 KR KR1020197030422A patent/KR20190120436A/ko not_active Application Discontinuation
- 2010-06-23 CN CN2010800370827A patent/CN102480967A/zh active Pending
- 2010-06-23 EP EP10792599.2A patent/EP2445349B1/en active Active
- 2010-06-23 CA CA2766642A patent/CA2766642C/en active Active
- 2010-06-23 AP AP2012006064A patent/AP2012006064A0/xx unknown
- 2010-06-23 US US12/821,571 patent/US9023877B2/en not_active Expired - Fee Related
- 2010-06-23 KR KR1020127001505A patent/KR101812054B1/ko active IP Right Grant
- 2010-06-23 JP JP2012517679A patent/JP5932640B2/ja not_active Expired - Fee Related
- 2010-06-23 PT PT107925992T patent/PT2445349T/pt unknown
- 2010-06-23 KR KR1020187008142A patent/KR20180032689A/ko active Application Filing
- 2010-06-23 CA CA3038405A patent/CA3038405C/en active Active
-
2012
- 2012-01-12 ZA ZA2012/00263A patent/ZA201200263B/en unknown
-
2015
- 2015-03-16 US US14/658,409 patent/US9345690B2/en not_active Expired - Fee Related
-
2016
- 2016-04-20 US US15/133,534 patent/US9820975B2/en active Active - Reinstated
- 2016-04-28 JP JP2016090237A patent/JP6188863B2/ja active Active
-
2017
- 2017-05-29 JP JP2017105934A patent/JP6464225B2/ja not_active Expired - Fee Related
- 2017-08-31 AU AU2017221828A patent/AU2017221828A1/en not_active Abandoned
- 2017-11-16 US US15/814,949 patent/US10363243B2/en active Active
-
2018
- 2018-11-12 HK HK18114444.3A patent/HK1255283A1/zh unknown
-
2019
- 2019-06-21 US US16/448,267 patent/US10912768B2/en active Active
-
2021
- 2021-02-08 US US17/169,907 patent/US11850237B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341877B (es) | Compuestos y métodos para tratar influenza. | |
PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
EA201200917A1 (ru) | Пролекарства ингибиторов плазменного калликреина | |
IN2012DN00869A (es) | ||
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
TN2012000171A1 (en) | Synthetic methods for spiro-oxindole compounds | |
CR20120417A (es) | Inhibidores de virus flaviviridae | |
EA201170241A1 (ru) | Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3 | |
GEP20156313B (en) | Substituted nucleotide analogs | |
MX2010009995A (es) | Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana. | |
GEP20146004B (en) | Pyridazinone compounds | |
MX2014002770A (es) | Nuevos derivados dihidroquinolina-2-ona. | |
MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
UA110338C2 (en) | Chemical compounds | |
MY160222A (en) | Polyheterocyclic compounds highly potent as hcv inhibitors | |
GEP20227353B (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
MX2011011272A (es) | Procesos e intermediarios. | |
EA201490015A1 (ru) | Композиции на основе дрожжей и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта | |
MX2019010600A (es) | Usos médicos para tratar hepatitis c. | |
MX2016001855A (es) | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. | |
EA201190293A1 (ru) | Пролекарства триптолида | |
MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
SG179082A1 (en) | Method for the preparation of an influenza virus | |
MX2012002385A (es) | Inhibidores macrociclicos de cinasa janus. | |
UA107346C2 (en) | Use of nifuratel to treat infections caused by atopobium species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |